[1] |
Kopetz VA, PennoM A, Hoffmann P, et al. Potential mechanisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon insight from a plasma proteomic approach[J].Int J Cardiol,2012,156(1):84-91.
|
[2] |
Wozakowska-Kaplon B, Niedziela J, Krzyzak P, et al.Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias[J].Cardiol J,2009,16(5):462-468.
|
[3] |
Iiu T, Xie Y, Zhou YJ, et al.Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180 day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions[J]. Chin Med J, 2009, 122(15):1732-1737.
|
[4] |
吴焱贤,吴赛珠,钟建开,等.冠状动脉内注射替罗非班对急诊介入治疗中慢血流现象的临床疗效[J].中华老年心脑血管病杂志,2013,15(2):139-142.
|
[5] |
赵学森,依仁科,董志.替罗非班的不同给药途径对急性ST段抬高型心肌梗死急诊PCI术中无复流的疗效对比[J].临床研究,2012,10(20):136-138.
|
[6] |
高晓丽,王东颖,刘英,等.急诊经皮冠状动脉介入治疗患者早期应用替罗非班的疗效及安全性[J].中国心血管病研究,2012,10(11):825-828.
|
[7] |
晋辉. 替罗非班对ST段抬高型AMI患者PCI后心肌灌注及心血管事件的影响[J].疑难病杂志,2011,10(1):7-9.
|
[8] |
尹建,徐强,唐刚,等.替罗非班在急性冠状动脉综合征中的应用进展[J].中华老年心脑血管病杂志,2012,14(4):441-443.
|
[9] |
Van't hof AWJ,Ernst N, Deboer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: Results of the ongoing tirofiban in myocardial infarction evaluation(On TIME) trial[J]. Eur Heart J, 2004, 25(10): 837-846.
|
[10] |
Deluca G, Gibson CM, Bellandi F, et al.Early glycoprotein IIb-Ⅲa inhibitors in primary angioplasty(EGYPT) cooperation: An individual patient data meta-analysis[J]. Heart, 2008, 94(12): 1548-1558.
|